Answers are grounded in this paper and cite their sources.
Despite national efforts to strengthen rational opioid use to balance effective pain management and misuse prevention, the absence of facility- and patient-level data precludes a comprehensive understanding of temporal trends and regional variations in opioid prescribing across the Chinese tiered healthcare system. This study aimed to examine the longitudinal trends in opioid prescribing in a province in central China, and to assess disparities across districts, healthcare facilities, and patient subgroups with respect to overall consumption and drug composition. This cross-sectional study included all opioid prescriptions issued between January 1, 2020, and December 31, 2023, across 1,117 healthcare facilities in the sample province. The primary outcome was opioid utilization, measured by prescription dosages standardized into morphine milligram equivalents (MMEs) and expressed as MMEs per 1,000 inhabitants. Consumption patterns were assessed according to Anatomical Therapeutic Chemical classification (N01AH and N02A), route of administration, and duration of action. A total of 3,927,378 opioid prescriptions were included. Annual N01AH opioid consumption increased by 31.1%, from 5,825.8 MMEs per 1,000 inhabitants in 2020 to 7,639.7 in 2023, whereas N02A consumption ranged from 2,355.4 to 2,392.8 MMEs per 1,000 inhabitants. Consumption was higher in urban than rural areas for both N01AH (9,607.7 vs. 2,308.3 MMEs per 1,000 inhabitants) and N02A opioids (2,871.3 vs. 1,706.5), and in high- than low-economic districts (N01AH, 8,611.9 vs. 4,034.2; N02A, 2,656.3 vs. 1,863.4). Prescribing was dominated by parenteral opioids (80.3%), especially in urban areas (83.0%) and primary care facilities (90.9%). Remifentanil and sufentanil were the most frequently prescribed N01AH opioids, increasing from 2,950.6 and 2,524.7 MMEs per 1,000 inhabitants in 2020 to 4,476.8 and 2,951.3 in 2023. Oral morphine and oxycodone had the highest N02A consumption, ranging from 1,096.3 to 1,215.1 and from 412.4 to 456.5 MMEs per 1,000 inhabitants, respectively. Findings revealed increasing N01AH, relatively stable N02A use, and notable regional disparities, particularly in N01AH, in a province in central China from 2020 to 2023. Tailored, evidence-based prescribing guidelines and policy interventions that account for the distinct clinical contexts of opioid analgesics are needed to promote safe and appropriate opioid use. Not applicable.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: